We found no association of the HSD3B1 CC genotype with development of metastases (HR, 1.02; 95% CI, 0.63-1.67, P = .92); however, in patients who developed metastatic disease at any time, the HSD3B1 CC genotype was associated with worse PCSM from time of metastases (HR, 2.48; 95% CI, 1.34-4.58; P = .004). This evidence concerns the gene HSD3B1 and metastatic neoplasm.